Claims for Patent: 12,390,428

Summary for Patent: 12,390,428

Title:	Bupropion and dextromethorphan for reduction of suicide risk in depression patients
Abstract:	This disclosure relates to a method of treating depression and/or reducing risk of suicide, comprising administering a combination of about 90 mg to about 120 mg of bupropion hydrochloride, or a molar equivalent amount of another form of bupropion, and about 40 mg to about 50 mg of dextromethorphan hydrobromide, or a molar equivalent amount of another form of dextromethorphan. The combination may be administered twice a day to a human being suffering from major depressive disorder and having a score of 3 or greater on the Suicidality Item of the Montgomery-Åsberg Depression Rating Scale (MADRS-SI).
Inventor(s):	Herriot Tabuteau
Assignee:	Antecip Bioventures II LLC
Application Number:	US18/397,220
Patent Claims:	1. A method of treating depression and reducing risk of suicide, comprising selecting a human being suffering from major depressive disorder and having a score of 3 or greater on the Suicidality Item of the Montgomery-Åsberg Depression Rating Scale (MADRS-SI) and a score of at least 35 on the Montgomery-Åsberg Depression Rating Scale (MADRS), and administering a combination of about 90 mg to about 120 mg of bupropion hydrochloride, or a molar equivalent amount of another form of bupropion, and about 40 mg to about 50 mg of dextromethorphan hydrobromide, or a molar equivalent amount of another form of dextromethorphan, to a human being; wherein the combination is administered twice a day to the human being. 2. The method of claim 1, wherein the combination comprises about 105 mg of bupropion hydrochloride, or a molar equivalent amount of another form of bupropion, and about 45 mg of dextromethorphan hydrobromide, or a molar equivalent amount of another form of dextromethorphan. 3. The method of claim 1, wherein the combination is administered twice a day for at least one week. 4. The method of claim 1, wherein the combination is administered twice a day for at least two weeks. 5. The method of claim 1, wherein the combination is administered twice a day for at least six weeks. 6. The method of claim 1, wherein the MADRS-SI of the human being is reduced by at least 30% after the combination is administered to the human being twice a day for one week. 7. The method of claim 1, wherein the MADRS-SI of the human being is reduced by at least 50% after the combination is administered to the human being twice a day for two weeks. 8. The method of claim 1, wherein the MADRS-SI of the human being is reduced by at least 60% after the combination is administered to the human being twice a day for four weeks. 9. The method of claim 1, wherein after eight days of administration of the combination twice a day, the Cmax of dextromethorphan in the human being is increased about 15-to about 25-fold as compared to administration of a single dose of the combination. 10. The method of claim 1, wherein after eight days of administering the combination twice a day, the Cmin of dextromethorphan in the human being is increased about 35-to about 45-fold as compared to administering a single dose of the combination. 11. The method of claim 1, wherein after eight days of administering the combination twice a day, the AUC0-12 of dextromethorphan in the human being is increased about 25-to about 45-fold as compared to administering a single dose of the combination. 12. The method of claim 2, wherein after eight days of administering the combination twice a day, the Cmax of dextromethorphan in the human being is about 75 ng/ml to about 80 ng/ml. 13. The method of claim 2, wherein after eight days of administering the combination twice a day, the Cmin of dextromethorphan is about 42 ng/ml to about 50 ng/mL. 14. The method of claim 2, wherein after eight days of administering the combination twice a day, the AUC0-12 of dextromethorphan in the human being is about 755 ng·hr/mL. 15. The method of claim 2, wherein after eight days of administering the combination twice a day, the Cmax of bupropion in the human being is about 85 ng/ml to about 90 ng/ml. 16. The method of claim 2, wherein after eight days of administering the combination twice a day, the Cmin of bupropion is about 25 ng/ml to about 35 ng/ml. 17. The method of claim 2, wherein after eight days of administering the combination twice a day, the AUC0-12 of bupropion in the human being is about 660 ng·hr/mL to about 670 ng·hr/mL.